Literature DB >> 7840598

Antimicrobial susceptibilities of clinical isolates of Acinetobacter baumannii from Singapore.

B G Kuah1, G Kumarasinghe, J Doran, H R Chang.   

Abstract

The in vitro activities of 17 antimicrobial agents alone or in combination against 70 clinical isolates of Acinetobacter baumannii from Singapore were determined by broth microdilution. The MICs of amoxicillin, ampicillin, ceftazidime, ceftriaxone, gentamicin, and piperacillin for 90% of the strains were > or = 128 micrograms/ml. Addition of sulbactam to ampicillin produced improved activity, whereas adding tazobactam to piperacillin did not. The MICs of amikacin, ciprofloxacin, and imipenem for 90% of the strains were 32, 32, and 16 micrograms/ml, respectively.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7840598      PMCID： PMC284774          DOI： 10.1128/AAC.38.10.2502

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Antimicrobial drug susceptibility of clinical isolates of Acinetobacter species (A. baumannii, A. haemolyticus, genospecies 3, and genospecies 6).

Authors:  W H Traub; M Spohr
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

Review 2.  Epidemiology of nosocomial infections due to Acinetobacter calcoaceticus.

Authors:  E Bergogne-Bérézin; M L Joly-Guillou; J F Vieu
Journal:  J Hosp Infect       Date:  1987-09       Impact factor: 3.926

3.  Infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus.

Authors:  C A Wood; A C Reboli
Journal:  J Infect Dis       Date:  1993-12       Impact factor: 5.226

4.  Antimicrobial susceptibility of Acinetobacter species.

Authors:  H Seifert; R Baginski; A Schulze; G Pulverer
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

5.  Multiple intensive care unit outbreak of Acinetobacter calcoaceticus subspecies anitratus respiratory infection and colonization associated with contaminated, reusable ventilator circuits and resuscitation bags.

Authors:  A I Hartstein; A L Rashad; J M Liebler; L A Actis; J Freeman; J W Rourke; T B Stibolt; M E Tolmasky; G R Ellis; J H Crosa
Journal:  Am J Med       Date:  1988-11       Impact factor: 4.965

6.  In vitro antimicrobial production of beta-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii.

Authors:  J Vila; A Marcos; F Marco; S Abdalla; Y Vergara; R Reig; R Gomez-Lus; T Jimenez de Anta
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

7.  In-vitro and in-vivo activities of antimicrobial agents against Acinetobacter calcoaceticus.

Authors:  Y Obana; T Nishino; T Tanino
Journal:  J Antimicrob Chemother       Date:  1985-04       Impact factor: 5.790

8.  Susceptibility survey of piperacillin alone and in the presence of tazobactam.

Authors:  J F Acar; F W Goldstein; M D Kitzis
Journal:  J Antimicrob Chemother       Date:  1993-01       Impact factor: 5.790

9.  Activity of imipenem, third-generation cephalosporins, aztreonam and ciprofloxacin against multi-resistant gram-negative bacilli isolated from Chilean hospitals.

Authors:  R Zemelman; H Bello; M Dominguez; G Gonzalez; S Mella; A Garcia
Journal:  J Antimicrob Chemother       Date:  1993-09       Impact factor: 5.790

10.  Nosocomial outbreaks due to amikacin-resistant tobramycin-sensitive Acinetobacter species: correlation with amikacin usage.

Authors:  Y Buisson; G Tran Van Nhieu; L Ginot; P Bouvet; H Schill; L Driot; M Meyran
Journal:  J Hosp Infect       Date:  1990-01       Impact factor: 3.926
  10 in total
  8 in total

1.  Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies.

Authors:  S Bajaksouzian; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

2.  In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak.

Authors:  M D Appleman; H Belzberg; D M Citron; P N Heseltine; A E Yellin; J Murray; T V Berne
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

3.  Activities of beta-lactams against Acinetobacter genospecies as determined by agar dilution and E-test MIC methods.

Authors:  M A Visalli; M R Jacobs; T D Moore; F A Renzi; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

4.  Widespread detection of PER-1-type extended-spectrum beta-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study.

Authors:  H Vahaboglu; R Oztürk; G Aygün; F Coşkunkan; A Yaman; A Kaygusuz; H Leblebicioglu; I Balik; K Aydin; M Otkun
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

5.  Characterization of the chromosomal cephalosporinases produced by Acinetobacter lwoffii and Acinetobacter baumannii clinical isolates.

Authors:  M Perilli; A Felici; A Oratore; G Cornaglia; G Bonfiglio; G M Rossolini; G Amicosante
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

6.  Emergence of resistant isolates of Acinetobacter calcoaceticus- A. baumannii complex in a Spanish hospital over a five-year period.

Authors:  M I García-Arata; T Alarcón; M López-Brea
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-06       Impact factor: 3.267

7.  Drug concentrations in the serum and cerebrospinal fluid of patients treated with cefoperazone/sulbactam after craniotomy.

Authors:  Qiang Wang; Yuanxing Wu; Biyao Chen; Jianxin Zhou
Journal:  BMC Anesthesiol       Date:  2015-03-13       Impact factor: 2.217

Review 8.  Antibiotic-Resistant Acinetobacter baumannii Increasing Success Remains a Challenge as a Nosocomial Pathogen.

Authors:  Ana Maria Gonzalez-Villoria; Veronica Valverde-Garduno
Journal:  J Pathog       Date:  2016-02-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.